NKTX - Nkarta, Inc.

1.51
-0.050   -3.311%

Share volume: 1,064,155
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$1.56
-0.05
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
16%
Profitability 0%
Dept financing 32%
Liquidity 50%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-7.36%
1 Month
-16.11%
3 Months
-35.74%
6 Months
-61.68%
1 Year
-82.74%
2 Year
-58.06%
Key data
Stock price
$1.51
P/E Ratio 
0.00
DAY RANGE
$1.46 - $1.65
EPS 
-$1.78
52 WEEK RANGE
$1.31 - $9.11
52 WEEK CHANGE
-$81.27
MARKET CAP 
175.716 M
YIELD 
N/A
SHARES OUTSTANDING 
70.559 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,306,482
AVERAGE 30 VOLUME 
$2,310,365
Company detail
CEO: Paul J. Hastings
Region: US
Website: nkartatx.com
Employees: 140
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens.

Recent news
loading